Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
出版年份 2019 全文链接
标题
Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
作者
关键词
-
出版物
HYPERTENSION
Volume 74, Issue 2, Pages 323-330
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2019-06-10
DOI
10.1161/hypertensionaha.119.12919
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
- (2018) Peter Willeit et al. LANCET
- Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
- (2017) Gregg C. Fonarow et al. JAMA Cardiology
- Endothelin receptor-specific control of endoplasmic reticulum stress and apoptosis in the kidney
- (2017) Carmen De Miguel et al. Scientific Reports
- The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated HypercholesterolemiaClinical Perspective
- (2016) Mary E. Haas et al. CIRCULATION
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE
- (2016) Karin Leander et al. CIRCULATION
- PCSK9 Association With Lipoprotein(a)Novelty and Significance
- (2016) Hagai Tavori et al. CIRCULATION RESEARCH
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
- (2016) Donald M. Lloyd-Jones et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR
- (2016) Kyrill S. Rogacev et al. PLoS One
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression and regulation of proprotein convertase subtilisin/kexin type 9 in vascular smooth muscle cells
- (2014) P. Stawowy et al. EUROPEAN HEART JOURNAL
- Randomized controlled trial using bosentan to enhance the impact of exercise training in subjects with type 2 diabetes mellitus
- (2014) Tim H. A. Schreuder et al. EXPERIMENTAL PHYSIOLOGY
- The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
- (2014) D. de Zeeuw et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Potential Effects of Reclassifying CKD as a Coronary Heart Disease Risk Equivalent in the US Population
- (2013) Meredith C. Foster et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Discontinuation of Statins in Routine Care Settings
- (2013) Huabing Zhang et al. ANNALS OF INTERNAL MEDICINE
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
- (2013) Ron T Gansevoort et al. LANCET
- Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
- (2012) Ding Ai et al. JOURNAL OF CLINICAL INVESTIGATION
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
- (2012) Clapton S. Dias et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial
- (2011) A. Rafnsson et al. DIABETOLOGIA
- Selective Endothelin-A Receptor Antagonism Reduces Proteinuria, Blood Pressure, and Arterial Stiffness in Chronic Proteinuric Kidney Disease
- (2011) Neeraj Dhaun et al. HYPERTENSION
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- (2011) Colin Baigent et al. LANCET
- Long-Term Administration of Endothelin Receptor Antagonist Improves Coronary Endothelial Function in Patients With Early Atherosclerosis
- (2010) Martin Reriani et al. CIRCULATION
- Early recognition and prevention of chronic kidney disease
- (2010) Matthew T James et al. LANCET
- Blood Pressure–Independent Reduction in Proteinuria and Arterial Stiffness After Acute Endothelin-A Receptor Antagonism in Chronic Kidney Disease
- (2009) Neeraj Dhaun et al. HYPERTENSION
- Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
- (2009) R. R. Wenzel et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Inflammation stimulates the expression of PCSK9
- (2008) Kenneth R. Feingold et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early Atherosclerosis
- (2008) Eugenia Raichlin et al. HYPERTENSION
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started